Inhibitors of animal cell motility and growth
View Patent ↗Cell motility and growth inhibitors, including compounds of the general structural formula and use of the cell motility and cell growth inhibitors, and pharmaceutically acceptable salts, prodrugs, and solvates thereof, as therapeutic agents, are disclosed.
1. A method of controlling progression of a cancer through metastasis in a male or female animal suffering from a colon cancer, lung cancer, or breast cancer comprising administering a therapeutically effective amount of (a) a compound having a formula
wherein R 1 is selected from the group consisting of C(═O)C 3-8 cycloalkenyl, C(═O)C≡C—R b and
R 2 is selected from the group consisting of C 1-3 alkyl and C 1-3 alkylenearyl;
R 3 is selected from the group consisting of hydrogen and C 1-3 alkyl;
R a is selected from the group consisting of hydrogen and C 1-3 alkyl;
R b is selected from the group consisting of hydrogen and C 1-3 alkyl;
R c is selected from the group consisting of hydrogen and C 1-3 alkyl; or
a pharmaceutically acceptable salt thereof,
and (b) a second therapeutically active ingredient used in a treatment of the cancer, wherein the second therapeutically active ingredient is a chemotherapeutic agent or radiation.
2. The method of claim 1 wherein (a) and (b) are administered simultaneously or sequentially.
3. The method of claim 1 wherein the compound has a structure
4. The method of claim 1 wherein the compound has a structure
5. The method of claim 1 wherein the compound has a structure
6. The method of claim 1 wherein R 3 is hydrogen; R 2 is selected from the group consisting of hydrogen, isopropyl, and methyl; R a is hydrogen or methyl; R b is selected from the group consisting of hydrogen, methyl, and ethyl.
7. The method of claim 1 wherein R 2 is selected from the group consisting of hydrogen, isopropyl, and methyl; and R 1 is selected from the group consisting of —C(═O)CH═CHCH 3 , —C(═O)CH═CH 2 , —C(═O)CH═CHC 2 H 5 ,
8. The method of claim 1 wherein the compound has a structure
9. The method of claim 1 wherein the compound has a biological IC 50 value of about 50 μM or less.
10. The method of claim 1 wherein the compound is (4S)-3-((E)-2-butenoyl-4-benzyl-2-oxazolidinone.
11. The method of claim 1 wherein the second therapeutically active ingredient is a chemotherapeutic agent and the cancer is colon cancer, lung cancer, or breast cancer.
12. The method of claim 1 wherein the second therapeutically active ingredient is radiation, and the cancer is colon cancer, lung cancer, breast cancer, or rectal carcinoma.